Primary Hyperoxaluria Type 1 Treatments

Find Primary Hyperoxaluria Type 1 Treatments

Brand Name

Oxlumo

Generic Name
Lumasiran
View Brand Information
FDA approval date: November 23, 2020
Form: Injection

What is Oxlumo (Lumasiran)?

OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 to lower urinary and plasma oxalate levels in pediatric and adult patients [see Clinical Pharmacology (1.
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

Retrospective and Prospective Follow-up of Patients With Primary Hyperoxaluria Type 1 Treated With Lumasiran in France - DAILY-LUMA

Summary: Primary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by mutation in the AGXT gene encoding the hepatic peroxisomal enzyme AGT. Reduced AGT activity results in increased glyoxylate and oxalate production, causing the formation of kidney stones, nephrocalcinosis and renal failure. Clinical trials of Lumasiran have provided information on the efficacy and safety of Lumasiran in the tre...